IRIS
DE BELLIS, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.640
AS - Asia 2.096
EU - Europa 1.760
SA - Sud America 600
Continente sconosciuto - Info sul continente non disponibili 285
AF - Africa 93
OC - Oceania 13
Totale 11.487
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.433
SG - Singapore 819
IT - Italia 637
CN - Cina 531
BR - Brasile 475
HK - Hong Kong 222
SE - Svezia 219
RU - Federazione Russa 192
VN - Vietnam 137
DE - Germania 128
FI - Finlandia 125
FR - Francia 124
UA - Ucraina 102
GB - Regno Unito 97
CA - Canada 94
BD - Bangladesh 89
IN - India 67
ID - Indonesia 44
MX - Messico 38
AR - Argentina 37
JP - Giappone 27
CI - Costa d'Avorio 26
NL - Olanda 25
TR - Turchia 23
EC - Ecuador 22
BE - Belgio 18
CO - Colombia 18
IQ - Iraq 17
AT - Austria 16
CR - Costa Rica 16
ES - Italia 16
VE - Venezuela 16
ZA - Sudafrica 16
IE - Irlanda 15
PK - Pakistan 14
PH - Filippine 12
AU - Australia 11
CL - Cile 11
HN - Honduras 11
KE - Kenya 11
MA - Marocco 11
MY - Malesia 11
PL - Polonia 11
TT - Trinidad e Tobago 11
SA - Arabia Saudita 10
SV - El Salvador 10
IR - Iran 9
NI - Nicaragua 9
PY - Paraguay 8
AE - Emirati Arabi Uniti 7
IL - Israele 7
UZ - Uzbekistan 7
CZ - Repubblica Ceca 6
DZ - Algeria 6
GP - Guadalupe 6
CW - ???statistics.table.value.countryCode.CW??? 5
KR - Corea 5
LT - Lituania 5
PE - Perù 5
EG - Egitto 4
NP - Nepal 4
OM - Oman 4
PA - Panama 4
UY - Uruguay 4
AL - Albania 3
BO - Bolivia 3
EE - Estonia 3
ET - Etiopia 3
GR - Grecia 3
JM - Giamaica 3
JO - Giordania 3
LB - Libano 3
PS - Palestinian Territory 3
SC - Seychelles 3
TH - Thailandia 3
TN - Tunisia 3
AO - Angola 2
AZ - Azerbaigian 2
CH - Svizzera 2
GT - Guatemala 2
HR - Croazia 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LK - Sri Lanka 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
SN - Senegal 2
TW - Taiwan 2
AM - Armenia 1
BF - Burkina Faso 1
BH - Bahrain 1
BS - Bahamas 1
BT - Bhutan 1
CY - Cipro 1
EU - Europa 1
Totale 11.197
Salva come PNG Salva come JPEG
Città #
Ashburn 681
Dallas 673
Fairfield 500
Singapore 416
Woodbridge 386
Chandler 351
San Jose 328
Houston 274
Cambridge 231
Hong Kong 220
Jacksonville 219
Seattle 199
Wilmington 198
Nyköping 186
Ann Arbor 185
Milan 176
Beijing 130
Council Bluffs 118
Los Angeles 114
New York 92
Bari 87
Nanjing 72
Roxbury 67
Lawrence 64
Lauterbourg 61
Rome 59
Helsinki 56
Santa Clara 52
São Paulo 51
Des Moines 45
Ho Chi Minh City 42
Brooklyn 40
Boardman 39
Princeton 39
Bitetto 38
Inglewood 33
Bitonto 28
Jakarta 28
Abidjan 25
Dearborn 25
Montreal 25
San Diego 25
Chicago 24
Buffalo 23
Hebei 23
Washington 23
Hanoi 22
Nanchang 21
Toronto 21
Dong Ket 20
Frankfurt am Main 20
London 20
Columbus 19
Brasília 18
Brussels 18
Rio de Janeiro 18
Jiaxing 17
Munich 17
Tokyo 17
Atlanta 16
Figino 16
North Bergen 16
Shenyang 15
Mexico City 14
Changsha 13
The Dalles 13
Falkenstein 12
Guangzhou 12
Nuremberg 12
Orem 12
San José 12
Dublin 11
Hefei 11
Redwood City 11
San Francisco 11
Denver 10
San Salvador 10
Turin 10
Turku 10
Managua 9
Miami 9
Nairobi 9
Tianjin 9
Warsaw 9
Belo Horizonte 8
Boston 8
Groningen 8
Guayaquil 8
Jinan 8
Johannesburg 8
Kuala Lumpur 8
Melbourne 8
Naples 8
Saint Augustine 8
Santiago 8
Stockholm 8
Brescia 7
Chennai 7
Falls Church 7
Kunming 7
Totale 7.435
Salva come PNG Salva come JPEG
Nome #
Proof-of-concept validation of the mechanism of action of Src tyrosine kinase inhibitors in dystrophic mdx mouse muscle: in vivo and in vitro studies 303
Involvement of voltage-gated sodium channels blockade in the analgesic effects of orphenadrine 273
A long-term treatment with taurine prevents cardiac dysfunction in mdx mice 265
Effects of Nandrolone in the counteraction of skeletal muscle atrophy in a mouse model of muscle disuse: molecular biology and functional evaluation 258
Contractile efficiency of dystrophic mdx mouse muscle: In vivo and ex vivo assessment of adaptation to exercise of functional end points 254
Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of Duchenne muscular dystrophy: a comparison with the gold standard, α-methyl prednisolone. 252
Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy 244
Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin 220
In vivo longitudinal study of rodent skeletal muscle atrophy using ultrasonography 213
Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity 210
Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia 209
On the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal muscles 209
Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options 208
Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy. 204
A new benzylated proline-like tocainide derivative is a potent use dependent skeletal muscle Na+ channel blocker with a potential antimyotonic activity 185
Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents 185
Change of chloride ion channel conductance is an early event of slow-to-fast fibre type transition during unloading-induced muscle disuse 176
BCAAs and Di-Alanine supplementation in the prevention of skeletal muscle atrophy: preclinical evaluation in a murine model of hind limb unloading 171
Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo 170
Ergogenic effect of bcaas and l-alanine supplementation: Proof-of-concept study in a murine model of physiological exercise 170
Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo 169
A new benzylated proline-like tocainide derivative is a potent use-dependent skeletal muscle Na+ channel blocker with a potential anti-myotonic activity 167
Synthesis of beta-proline like derivatives and their evaluation as sodium channel blockers 160
Dual action of mexiletine and its pyrroline derivatives as skeletal muscle sodium channel blockers and anti-oxidant compounds: Toward novel therapeutic potential 154
Paracrine Effects of IGF-1 Overexpression on the Functional Decline Due to Skeletal Muscle Disuse: Molecular and Functional Evaluation in Hindlimb Unloaded MLC/mIgf-1 Transgenic Mice 153
Calcium homeostasis is altered in skeletal muscle of spontaneously hypertensive rats cytofluorimetric and gene expression analysis 146
Statin‐induced myopathy: Translational studies from preclinical to clinical evidence 146
Therapeutic approaches to genetic ion channelopathies and perspectives in drug discovery 143
Searching for novel anti-myotonic agents: Pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide 141
Oxtr/TRPV1 expression and acclimation of skeletal muscle to cold-stress in male mice 139
Chiral mexiletine analogues as skeletal muscle voltage-gated sodium channel blocking agents 138
Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ 137
β‐Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation 137
Growth hormone secretagogues modulate inflammation and fibrosis in mdx mouse model of Duchenne muscular dystrophy 136
Identification of sites responsible for the potentiating effect of niflumic acid on ClC-Ka kidney chloride channels 132
Use-Dependent block of voltage-gated sodium channels by orphenadrine through binding at the local anesthetic receptor 130
Antitumorali 130
Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle 127
Branched-Chain Amino Acids and Di-Alanine Supplementation in Aged Mice: A Translational Study on Sarcopenia 126
Effects of GH secretagogues on resting chloride conductance of aged rat skeletal muscle 126
Combined modifications of mexiletine pharmacophores for new lead blockers of Nav1.4 channels 124
Stereospecific Synthesis of ‘‘para-Hydroxymexiletine’’ and Sodium Channel Blocking Activity Evaluation 124
Effects of Pleiotrophin Overexpression on Mouse Skeletal Muscles in Normal Loading and in Actual and Simulated Microgravity 124
Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs 121
Blockers of Skeletal Muscle Nav1.4 Channels: From Therapy of Myotonic Syndrome to Molecular Determinants of Pharmacological Action and Back. 117
Large screening of newly synthesized Mexiletine and Tocanide analogs as potent use-dependent blockers of skeletal muscle sodium channels: identification of the structural requirements for improving antimyotonic activity 113
Protein Kinase C-Theta Controls the CLC-1 Chloride Channel Function and Skeletal Muscle Phenotype: A Biophysical and Gene Expression Study in Pkc-Theta Null Mice 113
Newly synthesized mexiletine and tocainide analogues are potent use-dependent blockers of skeletal muscle sodium channels: potential implication for antimyotonic activity 113
Molecular determinants in mexiletine and tocainide structure to improve therapy of myotonia 108
Potent and stereoselective use-dependent block muscle Na+ channels by a new proline-like tocainide derivative 107
New molecular requirements of Toc derivatives bearing a novel class of Nav1.4 blockers 107
Potential benefits of taurine in the prevention of skeletal muscle impairment induced by disuse in the hindlimb-unloaded rat 106
Taurine administration to exercised mdx mouse ameliorates fore limb strength and electrophysiological properties of diaphragm and extensor digitorum longus muscles 104
Incresed rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the miotonic activity in vivo 104
Modification of resting chloride conductance during and after recovery from hindlimb unloading 99
Potent and stereoselective use-dependent block of skeletal muscle Na+ channels by a new proline-like tocainide derivative 99
Potent and stereoselective use-dependent block muscle Na+ channels by a new proline-like tocainide derivative 98
Modifications of ion channel activity and expression in soleus muscle fibers account for hypogravity-induced functional alterations 98
Evaluation of the dual action of new derivatives of mexiletine as use-dependent sodium channel blockers and antioxidant: potential therapeutic application in neuromuscular disorders 94
Modifications of ion channel activity and expression in soleus muscle fibers account for hypogravity-induced functional alterations 93
Evaluation of the dual action of new derivatives of mexiletine as usedependent sodium channel blockers and antioxidant: potential therapeutic application in neuromuscular disorders 92
Isosteric derivates of mexiletine: New potent use-dependent blockers of skeletal muscle sodium channels with potential antimyotonic activity 92
High affinity block of skeletal muscle sodium channels by newly synthesized analogs of tocainide and its proline-like derivatives 91
N‑Aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels 88
null 87
Molecular spatial geometry of CLC-K ligands: optimal requirements towards high affinity channel block 85
Isosteric derivatives of mexiletine: new potent use-dependent blockers of skeletal muscle sodium channels with potential antimyotonic activity 84
Stereospecific synthesis of “para-hydroxymexiletine“ amd sodium channel blocking activity evaluation 83
Molecolar determinants in Mexiletine and Tocainide structure to improve therapy of miotonia 82
Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents 80
Molecular spatial geometry of CLC-K ligands: optimal requirements towards high affinity channel block 80
LARGE SCREENING OF NEWLY SYNTHESIZED MEXILETINE AND TOCANIDE ANALOGS AS POTENT USE-DEPENDENT BLOCKERS OF SKELETAL MUSCLE SODIUM CHANNELS: IDENTIFICATION OF THE STRUCTURAL REQUIREMENTS FOR IMPROVING ANTIMYOTONIC ACTIVITY 80
Protein kinase C theta (PKCθ) modulates the ClC-1 chloride channel activity and skeletal muscle phenotype: a biophysical and gene expression study in mouse models lacking the PKCθ. 80
null 78
null 76
Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by n-benzyl analogs of tocainide-like compounds 74
null 72
Pharmacological activity of major metabolites of mexiletine on skeletal muscle sodium currents 70
null 70
null 70
null 68
Insights into the Activities and Usefulness of Deoxynojirimycin and Morus alba: A Comprehensive Review 68
Inhibition of skeletal muscle sodium currents by Mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile 64
Adverse effects of antiseizure medications: a review of the impact of pharmacogenetics and drugs interactions in clinical practice 53
null 49
Toward precision medicine in myotonic syndromes 47
Towards development of Nav1.7 channel modulators for pain treatment: A comparison of mexiletine effect in two cell models by automated patch clamp 39
Novel insights into the effects of JMV2894, a growth hormone secretagogue, in Duchenne muscular dystrophy: A preclinical study in the D2-mdx mouse model. 34
Branched-chain amino acid supplementation in a mouse model of ageing: Effects on age-related kidney fibrosis 32
Diaphragm‐specific effects of L‐citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy 29
Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance 8
Totale 11.487
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.015
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.015
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022445 0 0 0 0 16 42 25 25 51 50 87 149
2022/2023916 116 102 57 81 93 143 6 112 140 5 31 30
2023/2024332 23 54 22 32 31 79 16 12 4 17 11 31
2024/20251.527 65 48 97 49 71 148 173 147 105 71 203 350
2025/20263.870 474 173 778 326 346 157 368 93 337 331 120 367
2026/20271.131 120 158 309 537 7 0 0 0 0 0 0 0
Totale 11.487